Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 1/20 | 0.59 |
| ▸ | CCR1 | P32246 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | CCR5 | P51681 | 1/20 | 0.58 |
| ▸ | PARP1 | P09874 | 1/20 | 0.50 |
| ▸ | GLO1 | Q04760 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.42 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.42 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | BDKRB2 | P30411 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20470721 | 0.77 | CYP3A4 (0.37) | METAP2CCR1CCR5CYP1A2MAPT | |
| SCHEMBL806441 | 0.77 | CCR1 (0.64) | METAP2CCR1RAB9ACCR5PARP1 | |
| SCHEMBL2115749 | 0.77 | CCR1 (0.64) | METAP2CCR1RAB9ACCR5PARP1 | |
| SCHEMBL24694311 | 0.76 | CCR1 (0.61) | METAP2CCR1RAB9ACCR5PARP1 | |
| Neocuproine SCHEMBL29367091 | 0.75 | CCR1 (1.00) | METAP2CCR1RAB9ACCR5PARP1 | |
| Neocuproine SCHEMBL29639703 | 0.75 | CCR1 (1.00) | METAP2CCR1RAB9ACCR5PARP1 | |
| Neocuproine SCHEMBL124563 | 0.75 | CCR1 (1.00) | METAP2CCR1RAB9ACCR5PARP1 | |
| Neocuproine SCHEMBL11672280 | 0.75 | CCR1 (1.00) | METAP2CCR1RAB9ACCR5PARP1 | |
| SCHEMBL14988789 | 0.75 | METAP2 (0.60) | METAP2CCR1RAB9ACCR5PARP1 | |
| SCHEMBL18544257 | 0.75 | MTNR1A (0.47) | RAB9AMEN1KMT2ASMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3458444-B1 | HISTONE DEACETYLASE 6 INHIBITORS AND USE THEREOF | UNIV TAIPEI MEDICAL (TW) | 2022-06-22 | — | — | EP | disclosed |
| WO-2021013163-A1 | HISTONE DEACETYLASE 6 INHIBITORS AND METHOD FOR TREATING NEUROPATHIC PAIN | TAIPEI MEDICAL UNIVERSITY (CN) | 2021-01-28 | — | — | WO | disclosed |
| EP-3705477-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | Vertex Pharmaceuticals Incorporated (US) | 2020-09-09 | — | — | EP | disclosed |
| WO-2017200966-A1 | HISTONE DEACETYLASE 6 INHIBITORS AND USE THEREOF | DCB-USA LLC (US) | 2017-11-23 | — | — | WO | disclosed |
| EP-3216787-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | Vertex Pharmaceuticals Incorporated (US) | 2017-09-13 | — | — | EP | disclosed |
| US-20170133599-A1 | ORGANIC LIGHT-EMITTING DEVICE | SAMSUNG DISPLAY CO., LTD. (KR) | 2017-05-11 | — | — | US | disclosed |
| EP-2502911-B1 | Modulators of ATP-binding cassette transporters | VERTEX PHARMA (US) | 2017-04-05 | — | — | EP | disclosed |
| WO-2015188194-A1 | COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS | ISIS PHARMACEUTICALS, INC. (US) | 2015-12-10 | — | — | WO | disclosed |
| WO-2015179693-A1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | ISIS PHARMACEUTICALS, INC. (US) | 2015-11-26 | — | — | WO | disclosed |
| EP-2027108-B1 | HISTAMINE RECEPTOR ANTAGONISTS COMPRISING AN AZEPIN CORE | GLAXO GROUP LTD (GB) | 2010-01-13 | — | — | EP | disclosed |
| US-20090181950-A1 | Histamine Receptor Antagonists Comprising an Azepin Core | GLAXO GROUP LIMITED (GB) | 2009-07-16 | — | — | US | disclosed |
| EP-2027108-A1 | HISTAMINE RECEPTOR ANTAGONISTS COMPRISING AN AZEPIN CORE | Glaxo Group Limited (GB) | 2009-02-25 | — | — | EP | disclosed |
| WO-2007135081-A1 | HISTAMINE RECEPTOR ANTAGONISTS COMPRISING AN AZEPIN CORE | GLAXO GROUP LIMITED (GB) | 2007-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181950-A1 | Histamine Receptor Antagonists Comprising an Azepin Core | HRH2, HRH1, HRH4 | METAP2 1054/4885CCR1 519/4885RAB9A 1898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.